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Will there be an epidemic of HIV-
related chronic kidney disease in 
sub-Saharan Africa? Too soon to tell
Kara K. Wools-Kaloustian1 and Samir K. Gupta1
Most of what we know about HIV-related kidney disease comes 
from developed settings. However, the greatest population at risk 
resides in resource-limited areas where monitoring and treatment for 
kidney dysfunction are outside the scope of medical practice. More 
epidemiologic and prevention research is sorely needed.
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The pathobiology and epidemiology of 
HIV-associated nephropathy (HIVAN) 
have been well described in developed, 
Western countries.1 HIV-1 can infect renal 
tissue and initiate the cascade of histologic 
abnormalities of HIVAN that subsequently 
results in the classic clinical phenotype of 
nephrotic-range proteinuria and rapid dete-
rioration in renal function. Importantly, 
HIV-1 replication continues in this renal 
reservoir despite effective suppression of 
plasma viremia with antiretroviral therapy.2 
Fortunately, it appears that HIVAN may be 
reversible once antiretroviral therapy is 
initiated. In fact, a recently published large-
cohort study of HIV-infected patients in the 
United States demonstrated that renal func-
tion generally improves with antiretroviral 
therapy, with the greatest improvement in 
those with the lowest glomerular filtration 
rate prior to treatment initiation.3
What is unique about HIVAN is that 
it predominantly affects those of African 
descent.1 However, despite the availability of 
potent antiretroviral therapy as a treatment 
for HIVAN, mathematical models suggest 
that the prevalence of end-stage renal disease 
requiring renal replacement therapy will still 
exponentially increase in the United States.4 
This apparent paradox is primarily the result 
of an increasing and disproportionate infec-
tion rate in African Americans, many of 
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whom may develop severe nephropathy 
while not knowing of their HIV-positive 
status or having access to care.
Given the strong predisposition toward 
the development of HIVAN in blacks, it 
would seem reasonable to presume that 
the HIV epidemic in sub-Saharan Africa 
will soon lead to an additional epidemic of 
chronic kidney disease. There has been a 
growing anxiety and fear of this possibility 
for several reasons. First, limited clinical 
resources in most African settings have pre-
cluded simple laboratory testing for renal 
dysfunction, so monitoring for kidney dis-
ease may not be feasible. Second, dialysis is 
not available in most settings, so there is no 
effective treatment strategy for those who 
develop severe kidney disease. Finally, and 
most importantly, there has been a general 
lack of local data on the epidemiology of 
renal disease to help guide programmatic 
decisions on allocation of limited resources 
for diagnostics and treatment.
Without such data, can we reasonably 
extrapolate from our experience in the 
West? Not necessarily. There are several 
theoretical reasons why the prevalence of 
kidney disease in HIV-infected Africans 
and the response to antiretroviral therapy 
may not reflect what has been found in 
developed Western settings. First, most 
HIV-infected North Americans and west-
ern Europeans are infected with HIV-1 
clade B.5 Several different clades and 
recombinant forms of HIV-1 circulate in 
Africa. Clade C predominates in eastern 
and southern Africa, whereas other clades 
and recombinant forms of HIV-1 are found 
in central and western Africa. Furthermore, 
HIV type 2 (HIV-2) is also frequently 
found in some parts of western Africa. It 
appears that the rate of HIV disease pro-
gression may depend on the infecting clade 
or type.5 Thus, it is possible that differences 
in these clades or strains may result in dif-
ferences in the replication capacities within 
the isolated renal reservoir and thus lead 
to a diversity of clinical presentations. 
For example, our group found in a cross-
sectional study of untreated HIV-infected 
patients in western Kenya (typically HIV-1 
clade C) a 6% prevalence of proteinuria.6 
Although high compared with that of the 
general population, this prevalence rate is 
substantially lower than that found in HIV-
infected cohorts in the United States.7
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Another factor that may influence the 
effects of HIV on the kidney in African 
patients is host genetics. There is a great 
diversity of peoples in sub-Saharan Africa 
with highly varied genetic backgrounds 
that potentially lead to differences in HIV 
susceptibility and transmision.8 Given that 
the development of HIVAN is so strongly 
dependent on genetic predisposition, it 
would stand to reason that such differ-
ences in host characteristics may also lead 
to varied manifestations of kidney disease. 
Given that many HIV-infected blacks in 
the United States and Europe originated 
from western Africa, we cannot assume 
that central, eastern, and southern African 
patients with kidney disease would respond 
similarly to antiretroviral therapies. The 
additional variables of diet, environmental 
exposures, and access to health care would 
make epidemiologic extrapolations from 
developed settings to resource-limited 
areas of Africa even more suspect.
Fortunately, successful viral suppression 
in plasma has not yet appeared to depend 
on viral clade or strain.5 But does this mean 
that renal disease will also improve with 
treatment, as was recently demonstrated 
in the United States? The findings of Peters 
et al.9 (this issue) suggest that, at least in 
Uganda, this may be true. In this study, 
20% of the study cohort of HIV-infected 
patients initiating antiretroviral therapy 
had an estimated creatinine clearance less 
than 50 ml per minute at baseline. Treat-
ment with a standard combination of sta-
vudine, lamivudine, and nevirapine was 
then provided to the study participants. 
Renal function improved dramatically in 
nearly the entire cohort, with the most pro-
nounced increases in creatinine clearance 
in those with the worst renal dysfunction 
at baseline. These results closely mirror 
what was found in the United States study.3 
This nearly uniform improvement in renal 
function was also recently demonstrated 
in the Development of Antiretroviral 
Therapy trial based in Uganda and Zim-
babwe.10 In both of these African studies, 
antiretrovirals that normally require dose 
reduction in patients with decreased renal 
function were given at standard doses. 
As Peters et al.9 highlight, by not dose-
adjusting these medications, they avoided 
potential underdosing once renal function 
improved. Underdosing could potentially 
have risked therapeutic efficacy. Thus, they 
concluded that renal function may not 
need to be measured at the time of drug 
initiation, which could save precious clini-
cal resources. However, the authors also 
appropriately state that renal function may 
need to be monitored later in the course of 
therapy to identify drug-related nephrotox-
icities. This point was partially addressed in 
the Development of Antiretroviral Therapy 
trial, in which nearly three-quarters of the 
participants received tenofovir, a poten-
tially nephrotoxic drug. Overall, serious 
renal toxicities were infrequent in the 
Development of Antiretroviral Therapy 
trial, with no differences between those 
receiving tenofovir and those receiving 
other drugs. However, following an initial 
improvement in renal function through 60 
weeks of follow-up, there was a statistically 
significant, yet modest, decline of renal 
function in the tenofovir-receiving group 
after this time point.
The study by Peters et al.,9 in conjunc-
tion with emerging renal epidemiologic 
data from other parts of Africa, should 
provide reassurance that an uncontrolla-
ble epidemic of renal disease in resource-
poor settings is not a foregone conclusion 
(Figure 1). However, this comfort is only 
in the context of growing access to health 
care and availability of antiretroviral ther-
apy. We do not know as yet the likelihood 
of renal-related morbidity and mortal-
ity in patients not provided with potent 
combination antiretroviral treatment, 
many of whom either do not meet World 
Health Organization guidelines for ini-
tiation of therapy or do not have access to 
medical care. Additionally, there is a real-
istic possibility that direct adverse renal 
effects of antiretrovirals such as tenofovir 
or indirect effects of these drugs, namely 
stavudine-induced insulin resistance and 
dyslipidemia, may eventually cause renal 
dysfunction if these drugs are provided for 
a sufficient duration. Long-term follow-up 
of these patients is required before we can 
feel fully comfortable that a kidney disease 
epidemic will not occur in Africa.
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figure 1 | Potential differences in CKD rates with and without access to antiretroviral 
therapy. Dotted line represents projected prevalence of chronic kidney disease (CKD) without 
universal access to antiretroviral therapy. Solid line represents potential reduction of CKD 
prevalence with provision of antiretrovirals.
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Stem cells for kidney repair:  
useful tool for acute renal failure?
Takashi Yokoo1, Tetsuya Kawamura1 and Eiji Kobayashi2
Several cell types isolated from adult tissues have been reported to 
differentiate into mature kidney cells that may participate in renal 
repair after systemic administration. Chen et al. report that local 
mesenchymal stem cells derived from adult mouse kidneys are another 
source of cells with similar properties. Although these cells have the 
potential to differentiate into endothelial-lineage cell types, their 
therapeutic benefit to the ischemic kidney is mainly via the production 
of renoprotective factors.
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Acute renal failure (ARF) causes injury 
mainly to renal tubular epithelial cells. Over 
time, the injured tubules regenerate via cell 
proliferation, although the source of the 
cells that repopulate the injured nephron 
is not clear. Tissue regeneration may result 
from the proliferation of surviving dedif-
ferentiated cells, from renal stem cells that 
reside inside the kidney and migrate to the 
site of regeneration, or from bone marrow 
cells that gain access to the injured epithe-
lium and differentiate into mature cells.1 
It is now thought that most solid organs 
possess both endogenous and exogenous 
stem cells. After tissue injury, intrinsic tis-
sue stem cells replace damaged tissue as a 
first line of defense. If the pool of endog-
enous stem cells is exhausted, exogenous 
circulating stem cells are signaled to replen-
ish the pool and participate in tissue repair 
as a backup rescue system.2 In nephrology, 
several types of renal stem cells that are 
able to differentiate into tubular cells have 
been isolated from both adult kidney and 
bone marrow by techniques that are cur-
rently used to harvest stem cells from other 
organs, such as the heart and vessels.
The discovery of Y chromosome-positive 
tubular cells in kidney transplants from 
female donors after they recover from 
acute kidney failure3 has given rise to 
the hypothesis that some renal stem cells 
are resident in and are mobilized from 
the bone marrow. A number of studies 
have reported on the transplantation of 
bone marrow cells marked with LacZ, 
enhanced green fluorescent protein, or a 
genetic marker (Y chromosome) and their 
subsequent detection after the induction 
of renal damage. Renal tubular cells bear-
ing these markers have been detected, 
indicating that some fraction of the trans-
planted bone marrow cells (bulk fraction, 
hemato poietic stem cells, and/or mesen-
chymal stem cells (MSCs)) contributed to 
renal repair following experimental ARF. 
However, Duffield et al.4 recently demon-
strated that all the systems used in earlier 
studies to detect these markers, although 
well established, were capable of producing 
false-positive results, which could overesti-
mate the regenerative contribution of bone 
marrow-derived cells to renal repair.
Several attempts have been made to 
isolate tissue stem cells from adult kid-
ney. The techniques used have relied on 
the detection of cell-surface markers 
expressed universally in tissue stem cells, 
including CD133, Nestin, and CD24; 
microdissection and limiting-dilution 
methods; and the detection of side-pop-
ulation cells using Hoechst 33342 dye 
and fluorescence-activated cell sorting. In 
addition, on the basis of the assumption 
that tissue stem cells cycle very slowly and 
differentiate only as demanded by tissue 
turnover, slow-cycling cells tagged with 
the DNA marker bromodeoxyuridine 
are identified as stem cells. All these stem 
cells resident in tissue have the potential 
to differentiate into tubular cells and pro-
liferate following tissue injury. Plotkin 
and Goligorsky have previously reported 
that the adult mouse kidney contains 
MSCs with embryonic stromal charac-
teristics.5 Chen et al.6 (this issue) now 
report that local MSCs have the potential 
to differentiate into endothelial lineage 
and participate in renal repair through 
a local paracrine effect, mainly the pro-
duction of vascular endothelial growth 
factor to prevent microvascular dropout. 
Although it has been reported previously 
that MSCs derived from bone marrow 
can differentiate into endothelial cells 
and that their systemic administration 
can protect against ischemic renal fail-
ure through differentiation-independent 
mechanisms, Chen et al.6 shed light on 
the unique characteristics of local MSCs 
as useful vehicles for cell therapy to pro-
duce tissue regeneration after ARF. One 
